{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:47:44Z","timestamp":1782154064309,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100140"],"award-info":[{"award-number":["82100140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470994"],"award-info":[{"award-number":["32470994"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2024YFF1503000"],"award-info":[{"award-number":["2024YFF1503000"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022ZD0214200"],"award-info":[{"award-number":["2022ZD0214200"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tibtech.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:31:50Z","timestamp":1781872310000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A regenerative and programmable iPSC-derived platelet platform for universal drug delivery and immunotherapy"],"prefix":"10.1016","author":[{"given":"Lingna","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.05.017_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","article-title":"The dynamic role of platelets in cancer progression and their therapeutic implications","volume":"24","author":"Li","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2024.04.008","article-title":"Platelets: orchestrators of immunity in host defense and beyond","volume":"57","author":"Nicolai","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0015","series-title":"Platelets: tailoring metastasis treatment","author":"Mittelheisser","year":"2025"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0020","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/s41467-021-22674-3","article-title":"Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0025","doi-asserted-by":"crossref","first-page":"0011","DOI":"10.1038\/s41551-016-0011","article-title":"In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy","volume":"1","author":"Wang","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2016.02.036","article-title":"Genetic engineering of platelets to neutralize circulating tumor cells","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122478","article-title":"Platelet-derived drug delivery systems: pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond","volume":"306","author":"Zhu","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.copbio.2018.11.010","article-title":"Platelet for drug delivery","volume":"58","author":"Lu","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-023-00972-w","article-title":"Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery","volume":"30","author":"Burnouf","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0050","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0055","article-title":"Targeting 4-1BB for tumor immunotherapy from bench to bedside","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: a promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.36401\/JIPO-24-30","article-title":"4-1BB antibodies in oncology clinical trials: a review","volume":"8","author":"Schwartz","year":"2025","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0090","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/0008-5472.CAN-12-3343","article-title":"Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity","volume":"73","author":"Kwong","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0095","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00262-021-03001-7","article-title":"Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15","volume":"70","author":"McArdel","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0100","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41467-021-22898-3","article-title":"Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2680","article-title":"A phase 1\/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors","volume":"40","author":"Spira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44258-023-00009-9","article-title":"Hyperactivity of platelets and increased megakaryopoiesis in COVID-19 patients with acute respiratory distress syndrome","volume":"1","author":"Wang","year":"2023","journal-title":"Med-X"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1083\/jcb.201304054","article-title":"The incredible journey: from megakaryocyte development to platelet formation","volume":"201","author":"Machlus","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The platelet lifeline to cancer: challenges and opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8(+) T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0145","article-title":"In vitro generation of megakaryocytes and platelets","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0150","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1007\/s12015-022-10366-4","article-title":"Toward in vitro production of platelet from induced pluripotent stem cells","volume":"18","author":"Izady","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0155","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.3390\/ijms22158224","article-title":"Improving human induced pluripotent stem cell-derived megakaryocyte differentiation and platelet production","volume":"22","author":"Krisch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0160","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s00018-012-0995-4","article-title":"Pluripotent stem cells reveal the developmental biology of human megakaryocytes and provide a source of platelets for clinical application","volume":"69","author":"Takayama","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0165","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1182\/blood-2003-06-1773","article-title":"Production of functional platelets by differentiated embryonic stem (ES) cells in vitro","volume":"102","author":"Fujimoto","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0170","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V91.3.830","article-title":"Effects of cytokines on platelet production from blood and marrow CD34+ cells","volume":"91","author":"Norol","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jgg.2024.06.009","article-title":"Assessing the efficacy and safety of gemcitabine-induced thrombocytopenia\/neutropenia and thrombocytopenia interventions in zebrafish","volume":"51","author":"Deng","year":"2024","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0185","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1290","article-title":"DICE, an efficient system for iterative genomic editing in human pluripotent stem cells","volume":"42","author":"Zhu","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0190","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41598-020-57754-9","article-title":"Functional properties of human platelets derived in vitro from CD34(+) cells","volume":"10","author":"Do Sacramento","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0195","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.stemcr.2014.09.010","article-title":"Scalable generation of universal platelets from human induced pluripotent stem cells","volume":"3","author":"Feng","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0200","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0210","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970290","article-title":"Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity","volume":"13","author":"Reitinger","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0220","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-3510","article-title":"Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2R\u03b3null immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0230","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biomedicines12081850","article-title":"Beyond blood clotting: the many roles of platelet-derived extracellular vesicles","volume":"12","author":"Muttiah","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0235","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1084\/jem.20170879","article-title":"Platelets as autonomous drones for hemostatic and immune surveillance","volume":"214","author":"Li","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.2020008958","article-title":"Platelet MHC class I mediates CD8+ T-cell suppression during sepsis","volume":"138","author":"Guo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0245","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","article-title":"The role of platelets in immune-mediated inflammatory diseases","volume":"23","author":"Scherlinger","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/jfb16010015","article-title":"From blood to therapy: the revolutionary application of platelets in cancer-targeted drug delivery","volume":"16","author":"Xie","year":"2025","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1026386","article-title":"Platelets and platelet extracellular vesicles in drug delivery therapy: a review of the current status and future prospects","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0260","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.matt.2023.04.026","article-title":"T cell-mimicking platelet-drug conjugates","volume":"6","author":"Yang","year":"2023","journal-title":"Matter"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0265","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0270","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/s41587-024-02494-8","article-title":"Engineered platelets as targeted protein degraders and application to breast cancer models","volume":"43","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0275","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2012-01-407890","article-title":"Full reconstitution of human platelets in humanized mice after macrophage depletion","volume":"120","author":"Hu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0280","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2016-11-751099","article-title":"Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth","volume":"130","author":"Michael","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0285","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ccell.2022.08.004","article-title":"Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD","volume":"40","author":"Ma","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbac004","article-title":"Tumorigenicity risk of iPSCs in vivo: nip it in the bud","volume":"5","author":"Zhong","year":"2022","journal-title":"Precis. Clin. Med."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0295","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/bioengineering10070857","article-title":"Assessing tumorigenicity in stem cell-derived therapeutic products: a critical step in safeguarding regenerative medicine","volume":"10","author":"Wang","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.tibtech.2026.05.017_bb0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies","volume":"19","author":"Lee","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.05.017_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102543","article-title":"Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: an important step toward ensuring safe cell therapy","volume":"20","author":"Movahed","year":"2025","journal-title":"Stem Cell Rep."}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:53:58Z","timestamp":1782150838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":61,"alternative-id":["S0167779926002295"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.05.017","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A regenerative and programmable iPSC-derived platelet platform for universal drug delivery and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}